MISSION

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis

Retrieved on: 
Monday, November 15, 2021
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Safety, Baozou Big News Events, Migraine, Biomarker, Associate, PRR, Private Securities Litigation Reform Act, SLE, Investor, Chronic kidney disease, PD, Division, Ohio State University, Clinical trial, U.S. Securities and Exchange Commission, News, Disease, Lupus nephritis, COVID-19, Dermatomyositis, Ohio, Forward-looking statement, Dialysis, List of life sciences, Association, PTP, Patient, Disclosure, Week, Degenerative disease, Sec61, Pharmacokinetics, Diagnosis, Proteinuria, Death, Nephritis, Polymyositis, Webcast, Ohio State University Wexner Medical Center, CRR, Nasdaq, UPCR, Risk, Kidney failure, Immunosuppression, Pharmaceutical industry, Medical imaging, Lupus Nephritis, MISSION, KZR-616, Kezar Life Sciences, LUPUS NEPHRITIS, MISSION, KZR-616, KEZAR LIFE SCIENCES

The MISSION Phase 2 clinical trial is an open-label study to demonstrate the responder rate of KZR-616 in patients with active lupus nephritis.

Key Points: 
  • The MISSION Phase 2 clinical trial is an open-label study to demonstrate the responder rate of KZR-616 in patients with active lupus nephritis.
  • Patients in the MISSION Phase 2 trial do not receive KZR-616 as part of induction therapy, which represents a significant difference in comparison to other recently published trials in lupus nephritis.
  • For the interim analysis, five patients had reached end of treatment, and ten patients had reached week 13 of treatment.
  • Top-line data from the Phase 2 MISSION trial in patients with lupus nephritis are expected in the second quarter of 2022.

Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Health sciences, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Pharmacology, MISSION, KZR-616, Kezar Life Sciences, MISSION, KZR-616, KEZAR LIFE SCIENCES

MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.

Key Points: 
  • MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.
  • The Phase 1b portion is an open-label dose escalation study evaluating doses up to 75 mg of KZR-616 across 6 cohorts.
  • The primary objective of the Phase 1b portion of MISSION is to assess safety and tolerability.
  • The Phase 2 portion of the MISSION study evaluating KZR-616 in patients with LN is currently enrolling.

Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020

Retrieved on: 
Thursday, November 5, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Rheumatology, MISSION, PRESIDIO, KZR-616, Kezar Life Sciences

Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunoproteasome inhibitor, in two poster sessions during the American College of Rheumatology Annual Meeting (ACR Convergence 2020).

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunoproteasome inhibitor, in two poster sessions during the American College of Rheumatology Annual Meeting (ACR Convergence 2020).
  • Previously, Kezar has identified 45 mg and 60 mg as likely therapeutic doses to advance in its clinical development program.
  • Kezar is actively enrolling the PRESIDIO Phase 2 study (NCT04033926), a placebo-controlled, cross-over study of patients with DM and PM.
  • KZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Retrieved on: 
Thursday, September 17, 2020
Oncology, Health, Medical devices, Hospitals, Genetics, Clinical trials, Biotechnology, Cutaneous lupus erythematosus, Lupus, RTT, William Osler, Medical specialties, Clinical medicine, Medicine, MISSION, KZR-616, Kezar Life Sciences

MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.

Key Points: 
  • MISSION (NCT03393013) is a Phase 1b/2 clinical trial evaluating KZR-616 in SLE patients with and without nephritis.
  • The Phase 1b portion is an open-label dose escalation study which is evaluating doses up to 75 mg of KZR-616 across 6 cohorts, which has completed enrollment.
  • The Phase 2 portion of the MISSION study evaluating KZR-616 in patients with LN is currently enrolling.
  • Data generated from Phase 1a and 1b trials provide evidence that KZR-616 exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.